These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

59 related articles for article (PubMed ID: 23207506)

  • 1. ART regimen protects children from malaria.
    BMJ; 2012 Dec; 345():e8214. PubMed ID: 23207506
    [No Abstract]   [Full Text] [Related]  

  • 2. Antiretroviral agents and prevention of malaria in HIV-infected Ugandan children.
    Achan J; Kakuru A; Ikilezi G; Ruel T; Clark TD; Nsanzabana C; Charlebois E; Aweeka F; Dorsey G; Rosenthal PJ; Havlir D; Kamya MR
    N Engl J Med; 2012 Nov; 367(22):2110-8. PubMed ID: 23190222
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimalarial activity of sera from subjects taking HIV protease inhibitors.
    Redmond AM; Skinner-Adams T; Andrews KT; Gardiner DL; Ray J; Kelly M; McCarthy JS
    AIDS; 2007 Mar; 21(6):763-5. PubMed ID: 17413699
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lopinavir/ritonavir trough concentrations with the tablet formulation in HIV-1-infected women during the third trimester of pregnancy.
    Calza L; Manfredi R; Trapani F; Salvadori C; Colangeli V; Borderi M; Grossi G; Motta R; Viale P
    Scand J Infect Dis; 2012 May; 44(5):381-7. PubMed ID: 22263609
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Initial therapy for HIV: can less be more?
    Sax PE
    Lancet Infect Dis; 2014 Jul; 14(7):535-7. PubMed ID: 24783987
    [No Abstract]   [Full Text] [Related]  

  • 6. [Ritonavir-boosted lopinavir monotherapy due to intolerance to nucleoside reverse transcriptase inhibitors in an HIV-infected paediatric patient].
    Espiau M; Soler-Palacín P; Borrull A; Figueras C
    Enferm Infecc Microbiol Clin; 2011 Apr; 29(4):319. PubMed ID: 21334110
    [No Abstract]   [Full Text] [Related]  

  • 7. Barriers to simplified HIV treatment in low-resource settings.
    Moreira J
    Lancet Infect Dis; 2014 Dec; 14(12):1178-9. PubMed ID: 25455981
    [No Abstract]   [Full Text] [Related]  

  • 8. Initial treatment of HIV-1 infection.
    Schulz TR; Street AC
    N Engl J Med; 2008 Aug; 359(9):970; author reply 971. PubMed ID: 18753656
    [No Abstract]   [Full Text] [Related]  

  • 9. Initial treatment for HIV infection--an embarrassment of riches.
    Hirschel B; Calmy A
    N Engl J Med; 2008 May; 358(20):2170-2. PubMed ID: 18480210
    [No Abstract]   [Full Text] [Related]  

  • 10. [Not Available].
    Rivero A
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():1. PubMed ID: 25542867
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term (96-week) follow-up of antiretroviral-naïve HIV-infected patients treated with first-line lopinavir/ritonavir monotherapy in the MONARK trial.
    Ghosn J; Flandre P; Cohen-Codar I; Girard PM; Chaix ML; Raffi F; Dellamonica P; Ngovan P; Norton M; Delfraissy JF;
    HIV Med; 2010 Feb; 11(2):137-42. PubMed ID: 19682100
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
    Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
    J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Lopinavir/ritonavir in human immunodeficiency virus-infected women].
    Téllez MJ
    Enferm Infecc Microbiol Clin; 2014 Nov; 32 Suppl 3():22-5. PubMed ID: 25542872
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lopinavir-ritonavir versus nelfinavir for the initial treatment of HIV infection.
    Walmsley S; Bernstein B; King M; Arribas J; Beall G; Ruane P; Johnson M; Johnson D; Lalonde R; Japour A; Brun S; Sun E;
    N Engl J Med; 2002 Jun; 346(26):2039-46. PubMed ID: 12087139
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Critical drug interaction between ritonavir-boosted atazanavir regimen and non-nucleoside reverse transcriptase inhibitors.
    Poirier JM; Guiard-Schmid JB; Meynard JL; Bonnard P; Zouai O; Lukiana T; Jaillon P; Girard PM; Pialoux G
    AIDS; 2006 Apr; 20(7):1087-9. PubMed ID: 16603872
    [No Abstract]   [Full Text] [Related]  

  • 16. Can delavirdine substitute for ritonavir?
    TreatmentUpdate; 2001; 13(7):8. PubMed ID: 11794866
    [No Abstract]   [Full Text] [Related]  

  • 17. Incidence of resistance in a double-blind study comparing lopinavir/ritonavir plus stavudine and lamivudine to nelfinavir plus stavudine and lamivudine.
    Kempf DJ; King MS; Bernstein B; Cernohous P; Bauer E; Moseley J; Gu K; Hsu A; Brun S; Sun E
    J Infect Dis; 2004 Jan; 189(1):51-60. PubMed ID: 14702153
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lopinavir/ritonavir. (Kaletra).
    Res Initiat Treat Action; 2000 Dec; 6(4):16-8. PubMed ID: 11708169
    [No Abstract]   [Full Text] [Related]  

  • 19. Treatment of advanced HIV disease in antiretroviral-naïve HIV-1-infected patients receiving once-daily atazanavir/ritonavir or twice-daily lopinavir/ritonavir, each in combination with tenofovir disoproxil fumarate and emtricitabine.
    Uy J; Yang R; Wirtz V; Sheppard L; Farajallah A; McGrath D
    AIDS Care; 2011 Nov; 23(11):1500-4. PubMed ID: 21732894
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Selection of resistance in protease inhibitor-experienced, human immunodeficiency virus type 1-infected subjects failing lopinavir- and ritonavir-based therapy: mutation patterns and baseline correlates.
    Mo H; King MS; King K; Molla A; Brun S; Kempf DJ
    J Virol; 2005 Mar; 79(6):3329-38. PubMed ID: 15731227
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 3.